comorbidity-score

name	comorbidity-score
description	Calculate Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index for hospital admissions. Use for risk adjustment, mortality prediction, case-mix analysis, or comparing comorbidity burden across patient populations.
tier	validated
category	clinical

Comorbidity Scores

Two validated comorbidity indices for risk adjustment: Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index. Both are most commonly implemented using Quan 2005 ICD-9/ICD-10 coding algorithms, though other mapping algorithms exist.

M4Bench Use

In M4Bench, target concept tables listed in the task configuration are removed or unavailable in the agent database. Use this skill as procedural guidance and derive the requested output from available source or intermediate tables; do not rely on a precomputed target table or bundled SQL script.

When to Use This Skill

• Risk adjustment in outcome studies
• Mortality prediction models
• Case-mix comparison across cohorts
• Matching/stratification by comorbidity burden
• Resource utilization analysis

Index Comparison

Aspect	Charlson	Elixhauser
Categories	17 conditions	31 conditions
Output	Weighted score (0-33+)	Binary flags ± weighted score
Primary use	Mortality prediction	Risk adjustment, resource use
Age component	Included (0-4 points)	Not included
Weighting	Original 1987 fixed weights	Multiple options (unweighted, van Walraven)

Charlson: Single summary score; simpler models; established benchmarks.

Elixhauser: Granular profiles; flexible modeling (flags as covariates); captures conditions not in Charlson (obesity, depression, substance abuse).

Weighting Systems

Charlson Original Weights (1987)

Weight	Conditions
1	MI, CHF, PVD, CVD, Dementia, COPD, Rheumatic, PUD, Mild liver, DM w/o CC
2	DM w/ CC, Paraplegia, Renal disease, Cancer (non-metastatic)
3	Moderate/severe liver disease
6	Metastatic cancer, AIDS

Charlson Age Score

Age	Points
≤50	0
51-60	1
61-70	2
71-80	3
>80	4

Elixhauser van Walraven Weights (selected)

Weight	Conditions
+12	Metastatic cancer
+11	Liver disease
+9	Lymphoma
+7	CHF, Paralysis
+6	Other neurological, Weight loss
+5	Cardiac arrhythmias, Renal failure, Fluid/electrolyte
+4	Pulmonary circulation, Solid tumor
+3	Chronic pulmonary, Coagulopathy
+2	Peripheral vascular
-1	Valvular disease
-2	Blood loss anemia, Deficiency anemias
-3	Depression
-4	Obesity
-7	Drug abuse
0	HTN, DM, Hypothyroid, PUD, AIDS, RA, Alcohol, Psychoses

Critical Implementation Notes

1. Hierarchy Rules (applies to all implementations):

   • Liver: severe overrides mild
   • Diabetes: complicated overrides uncomplicated
   • Cancer: metastatic overrides solid tumor

2. ICD Code Algorithms: Quan 2005 provides the most widely used and validated ICD-9-CM and ICD-10-CM mappings for both indices. Other algorithms exist (e.g., Deyo 1992 for Charlson, AHRQ for Elixhauser) and may be appropriate depending on the study context.

3. Primary Diagnosis Exclusion: Elixhauser methodology excludes the primary diagnosis from comorbidity flagging (comorbidities should be conditions other than the reason for admission). Charlson typically includes all diagnoses. In administrative databases where the "primary" diagnosis field may not reflect the clinically principal diagnosis, this exclusion should be interpreted with caution.

Dataset-Specific Implementation Notes

MIMIC-IV

MIMIC-IV implementation details:

• Charlson ICD Mappings: Uses MIT-LCP mimic-code mappings (Quan 2005).
• Elixhauser ICD Mappings: ICD-10-CM mappings should be derived from the Quan 2005 original paper when needed.
• Diabetes Classification: Quan 2005 classifies E10.6 (diabetic foot ulcer) as "uncomplicated." Clinically debatable, but implementations follow Quan strictly.
• Primary Diagnosis Handling: Charlson includes all diagnoses. Elixhauser excludes seq_num = 1 per the original methodology. However, MIMIC's seq_num does not reliably indicate the clinically principal diagnosis — it reflects billing order, not clinical primacy. This is a known limitation; alternative approaches include filtering by DRG or accepting the imprecision.
• ICD Version Transition: MIMIC-IV spans ICD-9 (pre-Oct 2015) and ICD-10 (post-Oct 2015). Both versions mapped.

eICU

For eICU, three data sources are available, each with trade-offs:

Source	Coverage	Reliability	Notes
diagnosis.icd9code	Full (Charlson 17, Elixhauser 31)	Varies by site	Same Quan 2005 ICD-9 algorithms; ICD-9 only (pre-ICD-10 transition)
pasthistory	Partial (~12-14 Charlson categories)	More consistent	Structured text (e.g., "CHF", "COPD"); requires mapping table; less granular (cannot distinguish mild vs severe liver, DM with vs without CC)
apacheapsvar	Limited (~7 conditions)	High (required for APACHE IV)	AIDS, hepatic failure, immunosuppression, leukemia, lymphoma, metastatic cancer, cirrhosis

eICU limitations:

• ICD completeness varies by site: icd9code population ranges from near-complete to sparse across the 208 hospitals. A site-level completeness check (proportion of admissions with at least one ICD code) is recommended before using the ICD-only approach.
• No ICD-10 codes: eICU data (2014-2015) predates the ICD-10 transition. Only the ICD-9 portion of Quan 2005 algorithms applies.
• Primary diagnosis exclusion: The Elixhauser seq_num != 1 exclusion is even less reliable in eICU than MIMIC, as diagnosis ordering conventions vary across sites.
• Hybrid approach: Combining ICD-9 codes with pasthistory text matching and apacheapsvar flags may improve sensitivity but adds complexity and requires clinical validation of the text-to-category mapping.

References

• Charlson ME, et al. "A new method of classifying prognostic comorbidity." J Chronic Dis. 1987;40(5):373-83.
• Elixhauser A, et al. "Comorbidity measures for use with administrative data." Med Care. 1998;36(1):8-27.
• Quan H, et al. "Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data." Med Care. 2005;43(11):1130-9.
• van Walraven C, et al. "A modification of the Elixhauser comorbidity measures into a point system for hospital death." Med Care. 2009;47(6):626-33.